Aliases & Classifications for Dermatitis

MalaCards integrated aliases for Dermatitis:

Name: Dermatitis 12 54 44 15 70
Eczema 12 73 29 54 6 42 62 70
Skin Inflammation 12 6 15
Inflammatory Dermatosis 70


External Ids:

Disease Ontology 12 DOID:2723
MeSH 44 D003872
NCIt 50 C2983
SNOMED-CT 67 238538009
UMLS 70 C0011603 C0013595 C3875321

Summaries for Dermatitis

MedlinePlus : 42 Eczema is a term for several different types of skin swelling. Eczema is also called dermatitis. Most types cause dry, itchy skin and rashes on the face, inside the elbows and behind the knees, and on the hands and feet. Scratching the skin can cause it to turn red, and to swell and itch even more. Eczema is not contagious. The cause of eczema is unknown. It is likely caused by both genetic and environmental factors. Eczema may get better or worse over time, but it is often a long-lasting disease. People who have it may also develop hay fever and asthma. The most common type of eczema is atopic dermatitis. It is most common in babies and children, but adults can have it too. As children who have atopic dermatitis grow older, this problem may get better or go away. But sometimes the skin may stay dry and get irritated easily. Treatments may include medicines, skin creams, light therapy, and good skin care. You can prevent some types of eczema by avoiding Things that irritate your skin, such as certain soaps, fabrics, and lotions Stress Things you are allergic to, such as food, pollen, and animals NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Dermatitis, also known as eczema, is related to contact dermatitis and allergic contact dermatitis, and has symptoms including pruritus and exanthema. An important gene associated with Dermatitis is FLG (Filaggrin), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Coal tar and Isotretinoin have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and breast, and related phenotype is immune system.

Disease Ontology : 12 A skin disease characterized by itchy, erythematous, vesicular, weeping and crusting patches of skin.

PubMed Health : 62 About eczema: Eczema is a common, chronic, non-infectious skin condition. The main symptom of this inflammatory disease is a very itchy rash. It often affects children. In many cases eczema gets better as the years go by, and it may go away for a while or disappear altogether. Acute flare-ups can really affect quality of life. The itching can be especially bad, making it difficult to concentrate and sleep well. Some people are embarrassed if their rash is visible to others. By taking good care of your skin, using medication and avoiding irritants and other things that can trigger the eczema, it is usually possible to relieve the symptoms at least enough to live a fairly normal life. Eczema is sometimes also called "atopic eczema" or "atopic dermatitis."

Wikipedia : 73 Dermatitis (also known as eczema) is inflammation of the skin, typically characterized by itchiness,... more...

Related Diseases for Dermatitis

Diseases related to Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1702)
# Related Disease Score Top Affiliating Genes
1 contact dermatitis 33.5 IL4 IL31 FLG CCL27 CCL22 CCL17
2 allergic contact dermatitis 33.5 IL4 IL31 FLG CCL27 CCL22 CCL17
3 dermatitis, atopic 33.4 TSLP NOD2 IL4 IL31RA IL31 IL13
4 dermatitis herpetiformis 33.3 IL4 IL31 CCL11
5 irritant dermatitis 33.3 TSLP IL4 IL31 FLG
6 seborrheic dermatitis 33.2 ZNF750 FLG DSG1 BTD
7 eczema herpeticum 33.0 TSLP IL4 FLG
8 chromium allergic contact dermatitis 32.6 IL4 IL13
9 nickel allergic contact dermatitis 32.6 IL4 IL13
10 skin disease 32.5 TSLP IL4 IL31 IL13 FLG DSG1
11 allergic rhinitis 32.5 IL4 IL13 IGHE CCL17 CCL11
12 bullous pemphigoid 32.4 IL4 IL13 IGHE DSG1 CCL17 CCL11
13 pemphigoid 32.3 IL4 IL13 CCL11
14 netherton syndrome 32.3 IGHE FLG DSG1
15 hyper ige syndrome 32.3 IL4 IL13 IGHE CCL11
16 ige responsiveness, atopic 32.3 IL4 IL13 IGHE
17 allergic asthma 32.2 TSLP IL4 IL13 IGHE CCL17 CCL11
18 milk allergy 32.2 IL4 IL13 IGHE
19 egg allergy 32.1 TSLP IL4 IL13 IGHE FLG
20 rhinitis 32.1 TSLP IL4 IL13 IGHE CCL11
21 psoriasis 32.1 NOD2 IL4 IL31 IL13 FLG CCL27
22 food allergy 32.1 IL4 IL13 IGHE FLG
23 allergic disease 32.1 TSLP IL4 IL13 IGHE CCL22 CCL17
24 onchocerciasis 32.1 IL4 IL13 IGHE DSG1 CCL11
25 urticaria 31.9 IL4 IL31 IL13 IGHE CMA1
26 conjunctivitis 31.9 IL4 IL13 IGHE CCL11
27 hypereosinophilic syndrome 31.8 IL4 IL13 IGHE CCL17 CCL11
28 lichen planus 31.5 IL4 FLG DSG1
29 ichthyosis vulgaris 31.5 ZNF750 FLG DSG1
30 alopecia areata 31.4 IL4 IL13 FLG
31 respiratory allergy 31.4 TSLP IL4 IL13 IGHE
32 asthma 31.4 TSLP STAT1 NOD2 IL4 IL31 IL13
33 neurodermatitis 31.3 TSLP IL4 IL31RA IL31 IL13 FLG
34 allergic conjunctivitis 31.3 IL4 IL13 IGHE CCL11
35 chronic urticaria 31.2 IL4 IL13 IGHE
36 keratoconjunctivitis 31.2 TSLP IL4 IL13 CCL11
37 latex allergy 31.1 IL4 IL13 IGHE FLG
38 mite infestation 31.1 IL4 IL31 IL13 FLG
39 peanut allergy 31.1 IL4 IL13 IGHE FLG CCL22 CCL17
40 esophagitis 31.0 TSLP IL4 IL13 FLG DSG1 CCL11
41 schistosomiasis 31.0 IL4 IL13 IGHE
42 leprosy 3 31.0 NOD2 IL4 IL13
43 atopic keratoconjunctivitis 30.9 IL4 IGHE CCL22
44 esophagitis, eosinophilic, 1 30.9 TSLP IL4 IL13 FLG DSG1 CCL11
45 proteasome-associated autoinflammatory syndrome 1 30.8 STAT1 IL4 IL13 IGHE CCL11
46 otitis media 30.8 IL4 IGHE CCL11
47 lichen amyloidosis 30.7 IL31RA IL31
48 uveitis 30.7 NOD2 IL4 CCL11
49 pneumonia 30.7 IL4 IL13 CCL22 CCL17 CCL11
50 aspergillosis 30.7 NOD2 IL4 CCL17

Graphical network of the top 20 diseases related to Dermatitis:

Diseases related to Dermatitis

Symptoms & Phenotypes for Dermatitis

UMLS symptoms related to Dermatitis:

pruritus; exanthema

MGI Mouse Phenotypes related to Dermatitis:

# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.36 CARD11 CCL11 CCL17 CCL22 CMA1 IL13

Drugs & Therapeutics for Dermatitis

PubMed Health treatment related to Dermatitis: 62

Eczema is a chronic condition. Treatment cannot cure it, but regular skin care and medication can help to keep the itching and rash at bay. The main treatment options are: Basic treatment : Lipid -replenishing and moisturizing products (emollients ) are generously applied to the skin at least twice a day to keep it from drying out. This can help relieve itching and protect the skin from germs and irritants. Special soaps, liquid cleansers and shampoos : Normal soaps and products like shampoo or shower gel contain various substances that can dry out your skin . Special cleansing products without these substances are available to get around this problem. But basic treatment with emollients can usually compensate for the loss of moisture caused by normal soaps. Steroid creams : Eczema flare -ups are usually treated with steroid creams because they can relieve the itching and inflammation . They are typically used only for acute symptoms. But they are sometimes used at regular intervals together with moisturizing skin care products (basic treatment ): for example, as a "weekend treatment" where a steroid cream is applied on one or two days a week. Pimecrolimus and tacrolimus : Pimecrolimus and tacrolimus are two other medicines that can be used to treat eczema . They are not approved for use in children under the age of two years, though. These two medicines are also applied to the skin in a cream or ointment, and can be used if steroid products are not an option. This might be the case if steroid treatment is not tolerated or is ineffective. Pimecrolimus and tacrolimus may also be an option for long-term treatment of sensitive skin in the face and neck area. They can also be used on one or two days per week only, as described above. Other eczema treatment options include wet wraps, UV radiation and medications that suppress certain immune responses. Tablets containing these medicines are used if other treatments don't work, or if the eczema is very severe or affects large areas of skin . Because they have an effect throughout the entire body, they may have more extensive side effects than topical treatments. Allergy medications (antihistamines ) are also commonly used to relieve itching . But research has now shown that they are not suitable for treating eczema , whether used as tablets or a cream. People often try out herbal products or dietary supplements, such as evening primrose oil , borage oil, vitamin B6, vitamin E and zinc . But research hasn't shown that these products are effective. Many other treatments such as laser therapies or hyposensitization have not yet been studied enough, so they are not recommended by medical associations.

Drugs for Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 444)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Coal tar Approved Phase 4 8007-45-2
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
Desonide Approved, Investigational Phase 4 638-94-8 5311066
Glycerol Approved, Investigational Phase 4 56-81-5 753
Fluocinonide Approved, Investigational Phase 4 356-12-7 9642
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
Ethanol Approved Phase 4 64-17-5 702
carbamide peroxide Approved Phase 4 124-43-6
Omalizumab Approved, Investigational Phase 4 242138-07-4
Levocetirizine Approved Phase 4 130018-77-8 1549000
Menthol Approved Phase 4 2216-51-5 16666
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
Racepinephrine Approved Phase 4 329-65-7 838
Clobetasol Approved, Experimental, Investigational Phase 4 25122-41-2, 25122-46-7 32798 5311051
Desoximetasone Approved Phase 4 382-67-2 5311067
Montelukast Approved Phase 4 158966-92-8 5281040
Triclosan Approved, Investigational Phase 4 3380-34-5 5564
Brodalumab Approved, Investigational Phase 4 1174395-19-7
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Methylprednisolone aceponate Approved, Vet_approved Phase 4 86401-95-8
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Zinc oxide Approved Phase 4 1314-13-2
Allantoin Approved Phase 4 97-59-6 204
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 6447131 17753757
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
Alitretinoin Approved, Investigational Phase 4 5300-03-8 444795 449171
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
Alefacept Approved, Investigational, Withdrawn Phase 4 222535-22-0
Lactitol Approved, Investigational Phase 4 585-86-4 157355
Dapsone Approved, Investigational Phase 4 80-08-0 2955
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Cortisone Experimental Phase 4 53-06-5 222786
Halometasone Experimental Phase 4 50629-82-8
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
42 glucocorticoids Phase 4
43 Hormone Antagonists Phase 4
44 Bronchodilator Agents Phase 4
45 Lipid Regulating Agents Phase 4
46 Hypolipidemic Agents Phase 4
47 Histamine H1 Antagonists, Non-Sedating Phase 4
48 Epinephryl borate Phase 4
49 Leukotriene Antagonists Phase 4
50 Evening Primrose Phase 4

Interventional clinical trials:

(show top 50) (show all 1309)
# Name Status NCT ID Phase Drugs
1 Efficacy of KAM2904 Face Cream and KAM3008 Body Lotion Treatment in Children With Atopic Dermatitis (AD) Unknown status NCT01781663 Phase 4
2 A Randomized Controlled Pilot Study Comparing the Efficacy of Topical Coal Tar to Topical Corticosteroids in Children Aged 1 to < 16 Years With Moderate-severe Atopic Dermatitis Unknown status NCT03461302 Phase 4 Topical coal tar;Topical corticosteroids
3 Effect of Moisturizing Creams on Skin Barrier Function Unknown status NCT00771121 Phase 4 urea/lactic acid;Placebo
4 An Open Single Centre Evaluation of the Reactivity of the T.R.U.E. Test Quaternium-15 Patch and a Real Use Exposure in Subjects Known to Be Allergic to Quaternium-15 Unknown status NCT00311454 Phase 4 T.R.U.E.Test
5 Comparison of Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Experimentally Induced Skin Irritation Unknown status NCT00779792 Phase 4 clobetasol;triamcinolone acetonide;tacrolimus;glycerol;vehicle ointment (paraffin oil/soft white paraffin)
6 A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trials to Evaluate the Efficacy and Safety of Runzao Zhiyang Capsule in Treating Chronic Eczema Unknown status NCT02601222 Phase 4 Runzao zhiyang capsule;Runzaozhiyang capsule agent simulation;Urea cream
7 Clinical, Laboratorial and Quality of Life Trial to Evaluate the Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea. Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
8 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Receiving Radiation Therapy Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
9 A Randomized, Double-Blinded Study of Epiceram Versus Elidel in Pediatric Subjects With Mild to Moderate Atopic Dermatitis Completed NCT00460083 Phase 4 Elidel(R) (pimecrolimus 1%)
10 Bilateral Comparison Study of Elidel® (Pimecrolimus) Cream 1% and Hylatopic™ Plus Emollient Foam™ Emollient Foam in the Treatment of Subjects With Atopic Dermatitis Completed NCT01202149 Phase 4
11 Prospective, Randomized, Investigator-Blind, Controlled, Pilot Study Comparing Effect of Epiceram™ Device vs Standard of Care Therapy of Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) in Treatment of Atopic Dermatitis in Pediatric Subjects Completed NCT00616538 Phase 4 Fluticasone Propionate 0.05%
12 Effect of Sublingual Immunotherapy With Mite Extract in Patients With Atopic Dermatits: Placebo-controlled Double-blind Randomized Study Completed NCT03388866 Phase 4 Mite extract sublingual immunotherapy (SLIT)
13 Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit Completed NCT00654355 Phase 4 tacrolimus ointment
14 Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis Completed NCT00693693 Phase 4 hydrocortisone 17-butyrate 0.1% Cream preparation;hydrocortisone 17-butyrate 0.1% Ointment preparation;hydrocortisone 17-butyrate 0.1% Lipocream preparation
15 Prednisolone vs. Ciclosporine in Severe Atopic Eczema Completed NCT00445081 Phase 4 Prednisolone;Ciclosporine A
16 Quality of Life Study in Adults With Facial Eczema Completed NCT00120302 Phase 4 Pimecrolimus;Placebo
17 The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paediatric Atopic Eczema Completed NCT02300701 Phase 4 Xolair;Placebo
18 An Open-label Multicenter 12-month Long Term Study on Skin Reconstitution With Pimecrolimus Cream 1% in Adult Patients With Atopic Eczema and Corticosteroid Induced Skin Damage Completed NCT00367393 Phase 4 Pimecrolimus cream 1%
19 A 3-Month Open Label, National, Quality of Life , and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years ) With Atopic Dermatitis Completed NCT00484003 Phase 4 Pimecrolimus cream 1%
20 A Multi-Center Study to Assess the Impact of Topical Corticosteroids on the Safety and Efficacy of Protopic Ointment in the Short-Term Treatment of Atopic Dermatitis and to Assess Protopic in the Long-term Management of Atopic Dermatitis Completed NCT00106496 Phase 4 Protopic;Corticosteroid;placebo
21 Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) of Patients Intolerant to, or Dependant on, Topical Corticosteroids Completed NCT00121316 Phase 4 Pimecrolimus;Placebo
22 Interaction of Orally Administered Lactobacillus Rhamnosus GG With Skin and Gut Microbiota and Humoral Immunity in Infants With Atopic Dermatitis Completed NCT01148667 Phase 4
23 An Open -Label Study to Evaluate the Effect of Pandel Cream 0.1% on the Hypothalamic Pituitary Adrenal Axis in the Pediatric and Adult Population Completed NCT01137032 Phase 4 Pandel Cream 0.1%
25 Short Term Growth in Children With Atopic Dermatitis Completed NCT00236106 Phase 4 tacrolimus ointment 0.1%;mometasone furoate 0.1%
26 Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis Completed NCT00150059 Phase 4 Pimecrolimus Cream 1%
27 Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis Completed NCT00121381 Phase 4 Pimecrolimus plus topical corticosteroid (TCS);Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
28 An Exploratory Double-blind, Randomized, Vehicle-controlled, Paired Study to Evaluate the Efficacy and Safety of Concomitant Use of Elidel Cream 1% and Cutivate Cream 0.05% in Patients With Severe Lesions of Atopic Dermatitis (AD) Completed NCT00119158 Phase 4 Combination of pimecrolimus and fluticasone;pimecrolimus
29 Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis Completed NCT00117377 Phase 4 Pimecrolimus;Placebo
30 Randomized, Double Blind, Controlled Trial on Effectiveness Combined Probiotics in the Treatment of Atopic Dermatitis in Children Completed NCT02519556 Phase 4 Probiatop;Placebo
31 Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis. Completed NCT01177566 Phase 4 pimecrolimus
32 Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis Completed NCT01077882 Phase 4
33 Transepidermal Water Loss (TEWL) and Corneometry With Hydrogel Vehicle in the Treatment of Atopic Dermatitis - A Randomized, Investigator-Blind Pilot Study Completed NCT01065714 Phase 4 Hydrogel vehicle;Eucerin Lotion
34 An Open-Label Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis Completed NCT01049243 Phase 4 Fluocinonide Cream 0.1%
35 Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects Completed NCT00139581 Phase 4 Pimecrolimus;Pimecrolimus
36 Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis Completed NCT00130364 Phase 4 Pimecrolimus;Placebo
37 Study to Evaluate Resistant Disease/Max Adherence to Topical Treatments in Patients With Atopic Dermatitis and Psoriasis Completed NCT03050294 Phase 4 Desoximetasone 0.25% spray
38 An Investigator Blinded, Randomized, Controlled Study Comparing the Efficacy and Cost-Effectiveness of Aquaphor Healing Ointment, Atopiclair Nonsteroidal Cream (MAS063DP) and EpiCeram Skin Barrier Emulsion in Children With Mild to Moderate Atopic Dermatitis Completed NCT01093469 Phase 4 Atopiclair Nonsteroidal Cream;EpiCeram
39 Use of Altabax Ointment (Retapamulin 1%) BID for 7 Days in Treatment of Secondary Infection With Staphylococcus Aureus (MRSA and MSSA) and Streptococcus Pyogenes in Atopic Dermatitis Patients - Open Label Pilot Study Completed NCT01064947 Phase 4 Retapamulin 1%
40 Control of Therapy With Elidel vs Placebo in Patients With Atopic Dermatitis Using Bioengineering Methods Completed NCT00180141 Phase 4 Elidel-Creme
41 The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis Completed NCT00179959 Phase 4 Sodium hypochlorite (bleach) baths;Mupirocin ointment;Water;Petrolatum Ointment
42 Open Label Multicenter Study, 52 Weeks Duration, Using Pimecrolimus Cream 1% for the Long-term Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients Within a Usual Clinical Setting Completed NCT00509990 Phase 4 Pimecrolimus
43 A Multicenter, Randomized, Double-blind Clinical Study to Examine the Efficacy and Safety of Zarzenda in Comparison to Elidel in the Management of Mild to Moderate Atopic Dermatitis in Children and Adolescents Completed NCT00568412 Phase 4 Elidel
44 A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Montelukast (Singulair) in Participants Ages 1 - 8 Years Diagnosed With Atopic Dermatitis Induced by Food Allergens Completed NCT00557284 Phase 4 Montelukast;Placebo
45 A Phase IV, Open Label Study to Evaluate the Safety and Efficacy of Intramuscular (IM) Alefacept (Amevive) 15mg/wk in Subjects 18 Years and Older With Moderate to Severe Atopic Dermatitis Completed NCT00832585 Phase 4 Alefacept
46 Management of Pruritus With Xyzal in Atopic Dermatitis in a Randomized, Double-Blind, Placebo Controlled Study Completed NCT00884325 Phase 4 Levocetirizine dihydrochloride (Xyzal);placebo
47 Prospective Clinical Trial to Assess the Efficacy and Safety of EPOGAM 1000 in Patients With Atopic Dermatitis (Explorative Pilot Study) Completed NCT00878670 Phase 4 EPOGAM 1000
48 A Randomized, Investigator-Blind, Six-Week, Parallel Group, Multicenter Pilot Study to Compare the Safety and Efficacy of EpiCeram Skin Barrier Emulsion and Desonide Cream 0.05% in the Twice Daily Treatment of Pediatric Subjects With Moderate Atopic Dermatitis Completed NCT00828412 Phase 4 Desonide Cream 0.05%
49 Effects of a Novel Formulation of Fluocinonide 0.1% Cream on Skin Barrier Function in Atopic Dermatitis Completed NCT00819507 Phase 4 Fluocinonide
50 Proactive Treatment With Tacrolimus Ointment in Children With Moderate/Severe Atopic Dermatitis: A Randomized, Multicenter, Open-label Study Completed NCT01745159 Phase 4 tacrolimus

Search NIH Clinical Center for Dermatitis

Inferred drug relations via UMLS 70 / NDF-RT 51 :

alclometasone dipropionate
Clobetasol Propionate
cocoa butter
Cod Liver Oil
Colloidal oatmeal
Lactic acid
Methdilazine hydrochloride
OATMEAL 1 g in 1 g TOPICAL POWDER [Soothing Bath Treatment]
retinol acetate
retinyl palmitate
Vitamin A
Zinc Oxide

Cochrane evidence based reviews: dermatitis

Genetic Tests for Dermatitis

Genetic tests related to Dermatitis:

# Genetic test Affiliating Genes
1 Eczema 29

Anatomical Context for Dermatitis

MalaCards organs/tissues related to Dermatitis:

Skin, T Cells, Breast, Eye, Thymus, Neutrophil, Brain

Publications for Dermatitis

Articles related to Dermatitis:

(show top 50) (show all 44616)
# Title Authors PMID Year
Topical 0.05% clobetasol cream in the treatment of chronic hand eczema: A protocol for systematic review and meta-analysis. 61 42
33725820 2021
Analysis of dermoscopic characteristic for the differential diagnosis of palmoplantar psoriasis and palmoplantar eczema. 61 42
33592839 2021
Evaluation of hand hygiene and onset of hand eczema after the outbreak of SARS-CoV-2 in Munich. 42 61
33289485 2020
Elder siblings enhance the effect of filaggrin mutations on childhood eczema: results from the 2 birth cohort studies LISAplus and GINIplus. 54 61
20513523 2010
Increased risk of eczema but reduced risk of early wheezy disorder from exclusive breast-feeding in high-risk infants. 61 54
20236698 2010
Interleukin-4 receptor polymorphisms in asthma and allergy: relation to different disease phenotypes. 54 61
20002627 2010
Human leukocyte antigen (DR1)-DQB1*0501 and (DR15)-DQB1*0602 haplotypes are associated with humoral responses to early food allergens in children. 54 61
20016199 2010
Hyper-IgE syndrome with STAT3 mutation: a case report in Mainland China. 61 54
20490271 2010
Sporadic Blau syndrome with onset of widespread granulomatous dermatitis in the newborn period. 61 54
20199415 2010
Chromosome 11q13.5 variant associated with childhood eczema: an effect supplementary to filaggrin mutations. 54 61
20109745 2010
A multi-centre study of candidate genes for wheeze and allergy: the International Study of Asthma and Allergies in Childhood Phase 2. 54 61
20085599 2009
Melatonin inhibits the development of 2,4-dinitrofluorobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice. 61 54
19817972 2009
Filaggrin loss-of-function variants are associated with atopic comorbidity in pediatric inflammatory bowel disease. 61 54
19408338 2009
Contribution of itch-associated scratch behavior to the development of skin lesions in Dermatophagoides farinae-induced dermatitis model in NC/Nga mice. 54 61
18979107 2009
Filaggrin haploinsufficiency is highly penetrant and is associated with increased severity of eczema: further delineation of the skin phenotype in a prospective epidemiological study of 792 school children. 61 54
19681860 2009
Filaggrin mutations may confer susceptibility to chronic hand eczema characterized by combined allergic and irritant contact dermatitis. 61 54
19538184 2009
Filaggrin in atopic dermatitis. 54 61
19720209 2009
Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response. 61 54
19706451 2009
Exploring the repertoire of IgE-binding self-antigens associated with atopic eczema. 61 54
19541355 2009
Atopic dermatitis in adults: evaluation of peripheral blood mononuclear cells proliferation response to Staphylococcus aureus enterotoxins A and B and analysis of interleukin-18 secretion. 54 61
19469892 2009
Risk analysis of early childhood eczema. 54 61
19501236 2009
Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. 61 54
19351959 2009
Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease. 54 61
19501237 2009
A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. 61 54
19349982 2009
An interaction between filaggrin mutations and early food sensitization improves the prediction of childhood asthma. 61 54
19348926 2009
Clinical severity correlates with impaired barrier in filaggrin-related eczema. 54 61
18818676 2009
Early-life rotavirus and norovirus infections in relation to development of atopic manifestation in infants. 61 54
19032360 2009
Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency. 61 54
19088064 2009
[Relationship between gene polymorphism of CYP2E1, CYP1A1, IL-4 and medicamentosa-like dermatitis induced by trichloroethylene]. 61 54
19351467 2009
Elevated serum immunoglobulin E (IgE): when to suspect hyper-IgE syndrome-A 10-year pediatric tertiary care center experience. 54 61
19331717 2009
Wet-wrap treatment using dilutions of tacrolimus ointment and fluticasone propionate cream in human APOC1 (+/+) mice with atopic dermatitis. 54 61
18795918 2009
Hyper IgE (Job's) syndrome: a primary immune deficiency with oral manifestations. 54 61
19036057 2009
Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. 54 61
19147084 2009
FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. 54 61
19471859 2009
Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3. 61 54
18978467 2008
Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity. 61 54
18951619 2008
Early atopic disease and early childhood immunization--is there a link? 61 54
18925883 2008
Nickel sensitization, hand eczema, and loss-of-function mutations in the filaggrin gene. 61 54
19134432 2008
Classification of atopic hand eczema and the filaggrin mutations. 54 61
18976374 2008
Filaggrin in atopic dermatitis. 61 54
18774165 2008
Cytokine response after severe respiratory syncytial virus bronchiolitis in early life. 54 61
18760461 2008
Expired nitric oxide and airway reactivity in infants at risk for asthma. 54 61
18760452 2008
Novel immunological approaches in the treatment of atopic eczema. 61 54
18769195 2008
Analysis of the individual and aggregate genetic contributions of previously identified serine peptidase inhibitor Kazal type 5 (SPINK5), kallikrein-related peptidase 7 (KLK7), and filaggrin (FLG) polymorphisms to eczema risk. 61 54
18774391 2008
Change in prevalence of atopic dermatitis between 1986 and 2001 among children. 61 54
18702887 2008
Molecular pathogenesis and clinical implications of eczema herpeticum. 54 61
18620613 2008
Paediatric allergy diagnosis in primary care is improved by in vitro allergen-specific IgE testing. 61 54
18312533 2008
Polymorphisms in the interleukin 13 and GATA binding protein 3 genes and the development of eczema during childhood. 54 61
18410415 2008
Atopic eczema and the filaggrin story. 54 61
18620134 2008
Gene-environment interaction in the onset of eczema in infancy: filaggrin loss-of-function mutations enhanced by neonatal cat exposure. 54 61
18578563 2008

Variations for Dermatitis

ClinVar genetic disease variations for Dermatitis:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 STAT1 NM_007315.3(STAT1):c.821G>A (p.Arg274Gln) SNV Pathogenic 30085 rs387906760 GRCh37: 2:191859910-191859910
GRCh38: 2:190995184-190995184
2 FLG NM_002016.2(FLG):c.2282_2285del Microsatellite Pathogenic 16320 rs558269137 GRCh37: 1:152285077-152285080
GRCh38: 1:152312601-152312604
3 FLG NM_002016.1(FLG):c.1501C>T (p.Arg501Ter) SNV Pathogenic 16319 rs61816761 GRCh37: 1:152285861-152285861
GRCh38: 1:152313385-152313385
4 XDH NM_000379.4(XDH):c.1172C>T (p.Pro391Leu) SNV Uncertain significance 598996 rs1558697792 GRCh37: 2:31602803-31602803
GRCh38: 2:31379937-31379937
5 XDH NM_000379.4(XDH):c.3647C>A (p.Pro1216His) SNV Uncertain significance 335760 rs143981573 GRCh37: 2:31562482-31562482
GRCh38: 2:31339616-31339616

Expression for Dermatitis

Search GEO for disease gene expression data for Dermatitis.

Pathways for Dermatitis

Pathways related to Dermatitis according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
Show member pathways
13.8 STAT1 NOD2 IL4 IL31RA IL31 IL13
Show member pathways
13.49 TSLP IL4 IL31RA IL31 IL13 CCL27
Show member pathways
13.28 STAT1 IL4 IL13 CCL27 CCL22 CCL17
Show member pathways
13.08 STAT1 NOD2 IL4 IL31RA IL31 IL13
Show member pathways
12.75 STAT1 CCL27 CCL22 CCL17 CCL11
Show member pathways
12.27 TSLP STAT1 IL4 IL13
Show member pathways
12.22 STAT1 IL4 IGHE CCL11
Show member pathways
12.16 IL4 IL13 CCL17 CCL11
Show member pathways
12.15 CCL27 CCL22 CCL17 CCL11
10 11.65 STAT1 IL4 IL13
11 11.63 TSLP IL4 IL13
12 11.49 STAT1 IL4 IL13 IGHE CCL22 CCL11
13 11.36 IL4 IL13 CMA1 CCL11
14 11.34 IL4 IL13 CCL22
15 11.3 TSLP STAT1 CCL11
16 11.26 IL4 IGHE CCL17 CCL11
17 11.05 TSLP IL4 IL13
18 10.88 STAT1 CCL11
19 10.78 IL4 IL13 CCL27 CCL22 CCL17 CCL11
20 10.76 IL4 IL31 IL13 CCL22 CCL17 CCL11
21 10.66 IL4 IL13

GO Terms for Dermatitis

Cellular components related to Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 TSLP IL4 IL31 IL13 CMA1 CCL27
2 extracellular region GO:0005576 9.4 TSLP IL4 IL31 IL13 IGHE FAF2

Biological processes related to Dermatitis according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.98 TSLP STAT1 NOD2 IL4 IL31RA
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.81 NOD2 CCL22 CCL17 CCL11
3 chemotaxis GO:0006935 9.78 CCL27 CCL22 CCL17 CCL11
4 cellular response to interleukin-1 GO:0071347 9.74 CCL22 CCL17 CCL11
5 neutrophil chemotaxis GO:0030593 9.72 CCL22 CCL17 CCL11
6 chemokine-mediated signaling pathway GO:0070098 9.71 CCL22 CCL17 CCL11
7 immune response GO:0006955 9.7 IL4 IL13 IGHE CCL27 CCL22 CCL17
8 monocyte chemotaxis GO:0002548 9.63 CCL22 CCL17 CCL11
9 cellular response to interferon-gamma GO:0071346 9.62 STAT1 CCL22 CCL17 CCL11
10 positive regulation of B cell proliferation GO:0030890 9.61 IL4 IL13 CARD11
11 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.6 STAT1 NOD2
12 negative regulation of macrophage activation GO:0043031 9.59 IL4 IL31RA
13 macrophage activation GO:0042116 9.58 IL4 IL13
14 lymphocyte chemotaxis GO:0048247 9.58 CCL22 CCL17 CCL11
15 positive regulation of interleukin-13 production GO:0032736 9.56 TSLP IL4
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.56 TSLP IL4 IL31RA IL13
17 positive regulation of mast cell degranulation GO:0043306 9.52 IL4 IL13
18 positive regulation of mononuclear cell migration GO:0071677 9.49 IL4 CCL27
19 negative regulation of complement-dependent cytotoxicity GO:1903660 9.37 IL4 IL13
20 positive regulation of interleukin-10 production GO:0032733 9.26 TSLP NOD2 IL4 IL13
21 cytokine-mediated signaling pathway GO:0019221 9.23 STAT1 IL4 IL31RA IL31 IL13 IGHE

Molecular functions related to Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR chemokine receptor binding GO:0048020 9.43 CCL22 CCL17 CCL11
2 CARD domain binding GO:0050700 9.37 NOD2 CARD11
3 cytokine receptor binding GO:0005126 9.33 IL4 IL31 IL13
4 CCR3 chemokine receptor binding GO:0031728 9.32 CCL27 CCL11
5 chemokine activity GO:0008009 9.26 CCL27 CCL22 CCL17 CCL11
6 cytokine activity GO:0005125 9.23 TSLP IL4 IL31 IL13 CCL27 CCL22

Sources for Dermatitis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....